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Background. Current phenotypic testing for drug resistance in patients with tuberculosis is inadequate primarily
with respect to turnaround time. Molecular tests hold the promise of an improved time to diagnosis.
Methods. A target product proﬁle for a molecular drug-susceptibility test (DST) was developed on the basis of a
collaborative effort that included opinions gathered from researchers, clinicians, policy makers, and test developers
on optimal clinical and operational characteristics in settings of intended use. In addition, the current diagnostic
ecosystem and the diagnostic development landscape were mapped.
Results. Molecular DSTs for detecting tuberculosis in microscopy centers should ideally evaluate for resistance
to rifampin, ﬂuoroquinolones, isoniazid, and pyrazinamide and enable the selection of the most appropriate treat-
ment regimen. Performance characteristics of DSTs need to be optimized, but compromises can be made that de-
pend on the trade-off between a false-positive result and a false-negative result. The operational requirements of a test
will vary depending on the site of implementation. However, the most-important considerations pertain to quality
control, maintenance and calibration, and the ability to export data.
Conclusion. This target product proﬁle deﬁnes the needs as perceived by the tuberculosis stakeholder commu-
nity and attempts to provide a means of communication with test developers to ensure that ﬁt-for-purpose DSTs are
being developed.
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Progress has been made in improving tuberculosis cure
rates globally, but drug-resistant tuberculosis is threat-
ening that progress in many regions. In a 2014 report,
the World Health Organization (WHO) estimated that
only 8.5% of new tuberculosis cases and 17% of bacter-
iologically conﬁrmed cases requiring retreatment
received drug resistance testing and that, 480 000 people
developed multidrug-resistant (MDR) tuberculosis [1].
While the number of patients with MDR tuberculosis
or rifampin resistance detected worldwide increased
between 2012 and 2013 by 20%, more than half of
the estimated MDR tuberculosis cases still remain un-
diagnosed [1].The majority of these MDR tuberculosis
cases globally are estimated to be among new cases,
which is why the global tuberculosis strategy after
2015 calls for universal drug resistance testing [2].
Current phenotypic tests for drug resistance are inad-
equate primarily with respect to turnaround times and,
thus, time to initiation of therapy, which can inﬂuence
patient outcomes [3]. Molecular tests hold the promise
of an improved time to diagnosis, and the Xpert MTB/
RIF assay (Xpert; Cepheid, Sunnyvale, California) has
demonstrated the beneﬁt of combining both tuberculo-
sis detection and up-front resistance testing for rifam-
pin [4]. Rifampin was chosen as the target for that
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assay because patients with rifampin-resistant tuberculosis re-
quire treatment with second-line antituberculosis drugs [5]. A
number of other molecular tests are now in the pipeline, with
some aiming for an increased drug resistance testing portfolio
[6]. Several novel molecular tests are being developed for the pe-
ripheral laboratory setting, as opposed to the centralized, refer-
ral laboratory [7].
A tuberculosis test that provides results in <2 hours can en-
able a decision on which regimen to choose or a referral deci-
sion at the time of the patient’s ﬁrst visit to a tuberculosis
treatment center (ie, at the point of care) [8, 9]. This is especially
relevant over the coming years as novel alternative ﬁrst regi-
mens are emerging [10, 11]. Currently, there is only 1 ﬁrst-
line regimen, which includes isoniazid, rifampin, pyrazinamide,
and ethambutol (HRZE). An alternative regimen evaluated for
ﬁrst-line therapy, REMox (rifampin, moxiﬂoxacin, pyrazina-
mide, and ethambutol or isoniazid), was recently shown to be
inferior to HRZE in a phase 3 clinical study [12], but other ﬂu-
oroquinolone-based regimens are being explored [13]. Figure 1
shows the current tuberculosis drug pipeline. PaMZ (Pa824,
moxiﬂoxacin, and pyrazinamide) was shown to be effective in
a phase 2b trial [14] and will be evaluated in a phase 3 trial,
which started in November 2014. If the phase 3 study shows
this regimen to be beneﬁcial, it could be implemented over
the coming years (planned start, 2018) as an alternative to
the standard regimen.
A detailed, consensus-based target product proﬁle (TPP) is
necessary to align new tuberculosis diagnostic test development
with new tuberculosis drug regimens and outline the character-
istics of resistance testing that would meet medical and public
health needs at the level of the microscopy center, to inform test
developers [15].
METHODS
The development of the TPP described here was a collaborative
effort that included opinions from researchers, clinicians, policy
makers (global and national), and test developers. First, we
mapped the current diagnostic ecosystem to understand which
diagnostic tests are used in disease-endemic countries and
Figure 1. Tuberculosis Alliance pipeline. Reproduced with permission of the TB Alliance [13].
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speciﬁc healthcare settings. This was based on observations
from national tuberculosis programs and surveys [16]. In addi-
tion, market analyses in emerging economies (data for Brazil
only have been published to date; data for South Africa, India,
and China are to follow) [17] and a literature search of opera-
tional research on tuberculosis drug resistance testing were per-
formed. Second, >200 researchers in the ﬁeld and clinicians, as
well as clinical laboratory experts from low-burden and high-
burden countries, were surveyed about preferences for the pri-
oritization of drug resistance testing, considering currently
available and novel regimens (ie, PaMZ and other ﬂuoroquino-
lone-based regimens), interpretation and use of results with
suboptimal performance characteristics, and other related ques-
tions (Daniela Cirillo and Martina Casenghi, personal commu-
nication, 2014). In addition, mathematical models were used
where available to support decision making around optimal
test characteristics [18–20].
Third, a landscaping exercise was performed to create a
knowledge base of available molecular platform technologies
and molecular assays that could detect tuberculosis and differ-
ent resistance targets (FIND, unpublished internal data). This
was critical to inform the feasibility of achieving target speciﬁ-
cation within the expected time frame of development (eg, what
can be realistically achieved in terms of performance given a
5-year timeline). Key inputs for this exercise were gathered
from literature searches, a survey and discussions with the diag-
nostics industry and academic groups at trade shows and other
venues.
To gain a better understanding of the necessary operational
characteristics of the proposed diagnostic test, a survey was con-
ducted of the conditions present in microscopy centers of tu-
berculosis-endemic countries [21]. Data on the number of
microscopy centers and average number of tests performed
per center were gathered from publications (Demographic
and Health Surveys Project; http://www.measure dhs.com)
[22]. Needs associated with throughput, times to results, and
results documentation were obtained from clinician and
laboratory experts in the ﬁeld. Expert advice was also obtained
to inform speciﬁcations around data export and connectivity
of the diagnostic test (to enable eHealth and mhealth
solutions).
Data to inform the speciﬁc price range (ie, the lowest pre-
ferred and highest acceptable/affordable cost) for a diagnostic
test were difﬁcult to obtain. Ideally, the question of cost should
be addressed from several perspectives: What are the costs to the
test developers for development and production of a novel test?
What is the potential market of a test? What would be a range of
pricing that would make the test cost-effective (ie, the cost
would be justiﬁed by the gain in improved health outcomes
and the costs averted with the test, eg, shortened therapy or in-
fection control)? What price of the test would be affordable to
high-burden countries, considering their currently available
budget for tuberculosis diagnosis? Work is currently ongoing
to inform these estimates. A summary of an affordability anal-
ysis performed by Pantoja et al is presented as part of this
Supplement.
The original draft of the TPP was assembled by FIND with
input from all authors. Subsequently, it underwent several
rounds of revision, including contributions from the Working
Group on Assay Development in the Diagnostic Forum, man-
aged by the Critical Path to Tuberculosis Drug Regimens
(CPTR). A shortened version of the TPP was presented to a
large stakeholder audience that included >50 clinicians, imple-
menters, and representatives of countries and national tubercu-
losis programs in a meeting on high-priority target product
proﬁles convened in April 2014 by the WHO on behalf of the
Global Laboratory Initiative and the New Diagnostics Working
Group of the Stop TB Partnership. The ﬁnal TPP was published
by the WHO and partners in October 2014 [23]. This article
discusses the ﬁnal TPP.
RESULTS
A TPP was compiled using a test developers’ perspective with
the assumption that new ﬁrst-line treatment regimens will be
implemented and available, at least initially, in parallel to cur-
rent standard-of-care regimens. We subdivided the TPP by
scope, pricing, performance, and operational characteristics
(Tables 1–3). Each characteristic refers to a speciﬁc requirement
or speciﬁcation that is measurable. For each characteristics, a
minimal and optimal speciﬁcation was deﬁned. The minimal
speciﬁcation for a speciﬁc characteristic refers to the lowest ac-
ceptable speciﬁcation for that characteristic (although a test may
still be acceptable if shortcomings are only missed marginally
and are counterbalanced by other advantages). The optimal
speciﬁcation for a speciﬁc characteristic provides the ideal
value for that characteristic. Meeting the optimal characteristics
provides the greatest differentiation from existing methods and
the greatest inﬂuence for the end users, clinicians and patients.
Developers would ideally design and develop their solutions to
meet the optimal speciﬁcation in all characteristics. The optimal
and minimal speciﬁcations for each characteristic deﬁne a
range. The characteristics were speciﬁed with a development
timeline of <5 years in mind.
Scope of Use for the Test
The goal of the assay deﬁned in the TPP is to detect Mycobac-
terium tuberculosis and antituberculosis drug resistance near
the point at which case detection and/or treatment initiation
would normally occur (eg, microscopy centers and treatment
centers; Table 1). Information gained by testing would inform
decision making concerning current ﬁrst-line regimen selection
(HRZE, which will likely be available for the foreseeable future),
as well as novel regimens (such as PaMZ or other likely
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ﬂuoroquinolone-based regimens), and/or the need for further
testing for resistance to additional drugs. The target population
for testing as deﬁned in the TPP is all patients suspected of hav-
ing tuberculosis, with a special focus on those at high risk of
morbidity and mortality from drug-resistant tuberculosis,
such as people living with human immunodeﬁciency virus
(HIV), and those at high risk of having MDR tuberculosis
(eg, household contacts of patients with MDR tuberculosis, per-
sons with a history of prior tuberculosis, and persons who did
not respond to ﬁrst-line therapy).
Performance Characteristics
M. tuberculosis Detection
As shown in Table 2, the optimal sensitivity for M. tuberculosis
detection is higher than currently achieved by Xpert MTB/RIF
(>95%; 95% conﬁdence interval [CI], 90%–100%) when using
a single test, compared with 2 liquid cultures (smear negative,
>68%; smear positive, >99%) [51]. The optimal sensitivity trans-
lates into a limit of detection of <102 colony-forming units/assay
in 1 sample. The minimal sensitivity of the test should be >80%
(95% CI, 70%–90%), with retained high sensitivity in smear-
positive patients (smear positive, 99%) and a smear-negative
sensitivity of >60%.We set test speciﬁcity to allow use in the pop-
ulation of all patients who might be suspected of having tubercu-
losis. The speciﬁcity should be >98% for a single test, compared
with the optimal culture technique for the speciﬁc drug tested.
No cross-reactivity with other organisms, including nontubercu-
lous mycobacteria, is allowable. Multiplexing capability and the
ability to use the platform for different tests (eg, HIV load testing)
were judged as valuable features. Although not achievable with
existing molecular tests, a test should also be suitable for treat-
ment monitoring, to fully replace smear microscopy.
Resistance Testing
Testing for rifampin, ﬂuoroquinolones (including moxiﬂoxa-
cin), isoniazid, and pyrazinamide resistance was identiﬁed as
most useful for regimen selection in the near future (Table 2).
The TPP prioritized testing for drugs for which resistance-
causing mutations have been identiﬁed and are known to be
of clinically relevant frequency and in which resistance has
≥1of the following 3 consequences: it seriously affects treat-
ment efﬁcacy, increases the risk of resistance ampliﬁcation,
or strongly predicts resistance to other drugs. Fluoroquino-
lones and pyrazinamide resistance testing were included be-
cause, even if the clinical trial results for PaMZ are not
satisfactory, it is very likely that these drugs will be part of
novel regimens [13]. No speciﬁcation was made with respect
to whether testing for resistance to a drug should be included
together withM. tuberculosis detection or whether it should be
in a separate step. This decision will depend on many factors,
including which performance characteristics can be reached
for a certain drug, what the epidemiology of drug resistance
is, and what the trade-off might be for including the drug-
susceptibility test together with M. tuberculosis detection
(eg, in terms of time to diagnosis).
Considerations around speciﬁc drugs included were as fol-
lows. Rifampin is a key component of HRZE and is also an in-
dicator drug for resistance to additional drugs, particularly
pyrazinamide and isoniazid (ie, >90% of rifampin-resistant
strains are isoniazid resistant and 30%–90% are pyrazinamide
resistant) [30–32, 52]. Fluoroquinolone resistance is less closely
associated with rifampin resistance (10%–30% of rifampin-
resistant strains are ﬂuoroquinolone resistant) [52]. Moxiﬂoxa-
cin is a key component of PaMZ, and it is a suitable replacement
of isoniazid in case of isoniazid monoresistance and, along with
Table 1. Scope of Drug-Susceptibility Tests (DSTs) at Microscopy Centers
DST Characteristic Optimal/Minimal References
Goal Diagnosis of tuberculosis and detection of drug resistance, to inform decision making
about the optimal first-line regimen (HRZE, PaMZ, or other fluoroquinolone-based
regimens) for treatment and, possibly, to detect the presence of additional resistance
to second-line antituberculosis agents and the need for further testing
. . .
Target population Target groups are all patients suspected of having tuberculosis, with a special focus on
those at high risk of morbidity and mortality from drug-resistant tuberculosis, such as
people living with HIV and those at high risk of having MDR tuberculosis (eg,
household contacts of patients in whom MDR tuberculosis has been diagnosed and
persons with a history of tuberculosis, especially those for whom first-line therapy has
failed) in countries with a medium prevalence to a high prevalence of tuberculosis, as
defined by the WHOa
[1, 24]
Target user Healthcare worker with training necessary for performing smear microscopy
Lowest setting of implementation
(health system level)
Microscopy centers or higher levels of the healthcare system [21, 25–27]
Adapted with permission from [23].
Abbreviations: HIV, human immunodeficiency virus; HRZE, isoniazid, rifampin, pyrazinamide, ethambutol; MDR, multidrug resistant; PaMZ, Pa824, moxifloxacin,
pyrazinamide; WHO, World Health Organization.
a High-prevalence countries are thosewith >40 cases per 100 000 population, medium-prevalence countries are thosewith 20–40 cases per 100 000 population, and
low-prevalence countries are those with <20 cases per 100 000 population [24].
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other ﬂuoroquinolones, is part of the current regimens for
MDR tuberculosis [53].
Pyrazinamide is included in HRZE and PaMZ regimens and
is a key component for sterilization of infected sites. The prev-
alence of ﬂuoroquinolone and pyrazinamide resistance (in the
absence of rifampin resistance) is poorly deﬁned but is expected
to be <3% in most countries across all patients presenting for
testing (Matteo Zignol, WHO, personal communication,
2014), with higher values expected in countries where ﬂuoro-
quinolones are widely used as antibiotic for other infections
(eg, India and Pakistan). With this low prevalence, upfront test-
ing of all patients for ﬂuoroquinolone and pyrazinamide
Table 2. Performance Characteristics of Drug-Susceptibility Tests (DSTs)
Characteristic Optimal Minimal Reference(s)
Diagnostic sensitivity for M.
tuberculosis detection
Should be >95% for a single test, compared
with 2 liquid cultures; for smear-negative
tuberculosis, it should be >68%; for smear-
positive tuberculosis, it should be 99%
Should be >80% for a single test, compared
with culture (for smear-negative cases, it
should be >60%; for smear-positive cases,
it should be 99%)
[19]
Diagnostic specificity for M.
tuberculosis detection
Should be >98% for a single test, compared
with culture
Should be >98% for a single test, compared
with culture
[4, 28, 29]
Priority of drugs tested In order of decreasing importance: (1) RIF, (2) FQs (including MOX) (3) INH and PZA (equally
important), and (4) AG/CAP; optimally, all drugs would be included, but as a minimum at least
RIF should be included
[1, 30–36]
Diagnostic sensitivity for DST,
by reference standard
Genetic sequencing Should be >98% for detecting targeted SNPs
for resistance to RIF, FQs, PZA, INH, and
AG/ CAP, compared with genetic
sequencing
Should be >98% for detecting targeted SNPs
for resistance to RIF and 95% for detecting
targeted SNPs for resistance to FQs, PZA,
INH, and AG/ CAP, compared with genetic
sequencing
[1, 28, 37–
42]
Phenotypic DST >95% for detecting RIF, FQ, PZA, INH, and
AG/CAP resistance in comparison to
recommended phenotypic culture
reference DST for specific antituberculosis
agent
>95% for detecting RIF resistance; >90% for
detection of FQ, PZA, INH, and AG
resistance in comparison to recommended
phenotypic culture reference DST for
specific antituberculosis agent
[42, 43]
Diagnostic specificity for DST,
using genetic sequencing
as the reference standard
Should be ≥98% for any antituberculosis agent for which the test is able to identify resistance [1, 28, 37–
39, 42]
Limit of M. tuberculosis
detection during resistance
testing
First reaction Should be better than Xpert MTB/RIF for
tuberculosis case detection (ie, <4.5
genome equivalents/reaction and <102
CFU/assay, using 1 sample
Should be between smear microscopy and
Xpert MTB/RIF for tuberculosis case
detection (ie, 102–105 CFU/assay, using 1
sample)
[4, 29]
Second reaction Should be no worse than Xpert MTB/RIF for
tuberculosis case detection (ie, ≥4.5
genome equivalents/reaction and 131 CFU/
mL of sputum)
Should be between smear microscopy and
Xpert MTB/RIF for tuberculosis case-
detection (ie, 102–105 CFU/assay, using 1
sample)
[44]
Analytical specificity for M.
tuberculosis detection
No cross-reactivity with other organisms,
including nontuberculous mycobacteria
No cross-reactivity with other organisms,
including nontuberculous mycobacteria
. . .
Indeterminate results
detection, %
<2 <5 . . .
Reproducibility Interassay coefficients of variance should be ≤10.0% at the high and low extremes of the assay . . .
Interfering substances No interference should be caused by substances known to occur in the human respiratory and
pulmonary tracts, including blood that could potentially inhibit PCR, and substances used to
treat or alleviate respiratory disease or symptoms
. . .
Assay design Addition or removal of analytes should not require extensive analytical and clinical reverification
and revalidation of the assay
. . .
Treatment-monitoring
capability
Yes No . . .
Adapted with permission from [23].
Abbreviations: AG, aminoglycoside; CAP, capreomycin; CFU, colony-forming units; FQ, fluoroquinolone; HRZE, isoniazid, rifampin, pyrazinamide, ethambutol; INH,
isoniazid; MOX, moxifloxacin; M. tuberculosis, Mycobacterium tuberculosis; PCR, polymerase chain reaction; PZA, pyrazinamide; RIF, rifampin; SNP, single-
nucleotide polymorphism.
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Table 3. Operational Characteristics of Drug-Susceptibility Tests
Characteristic Optimal Minimal References
Sample type Sputum raw Sputum raw . . .
Acceptable range for sample
volume
Any sample from 0.1 mL to 10 mL is
acceptable
Any sample from <0.5 mL to 2 mL is
acceptable
. . .
Manual sample prep (total hands-
on steps after obtaining sample)
No steps or 1 step; precise volume
control and precise timing should not
be required
Maximum of 2 steps; precise volume
control and precise timing should
not be required
[21, 25]
Reagent integration All reagents should be contained in a
single device
A maximum of 2 external reagents
should be needed and, if required,
should be included in the test kit
. . .
Time-to-result <30 min (for detection and resistance
testing)
<2 h (for resistance testing alone) [45, 46]
Daily throughput per module >25 tests >5 tests . . .
Sample capacity and throughput Multiple samples should be able to be
tested at the same time; random
access should be possible
Batching should be possible . . .
Walkaway operation These features are required; there should
not be a need for operator intervention
once the sample has been placed into
or on the instrument
No more than 1 step of operator
intervention should be needed once
the sample has been placed into or
on the system
. . .
Biosafety Should have the same requirements as
the Xpert MTB/RIF assay
Should have the same requirements
as the Xpert MTB/RIF assay
[21, 25, 47]
Waste disposal
Solid material Should require no more than smear
microscopy; should have the possibility
of recycling some waste
Should require no more than Xpert
MTB/RIF
. . .
Infectious material Should require no more than Xpert MTB/
RIF
Should require no more than Xpert
MTB/RIF
. . .
Multiuse platform Yes None required . . .
Instrumentation A single integrated system that is modular
to allow throughput to be increased if
needed
Up to 2 instruments within the system
that are independent of each other
. . .
Power requirements Battery operated with the ability to run for
1 d on the battery and with recharging
capability (which could be solar
powered) and a circuit protector
Capable of running on standard
electricity plus an uninterrupted
power supply unit to enable a cycle
to be completed in case of a power
outage; a circuit protector should be
included; the uninterrupted power
supply and circuit protector must be
integrated within the system
[21, 25]
Maintenance/calibration Preventive maintenance should not be
needed until after 2 y or >5000
samples; an alert should be included to
indicate when maintenance is needed;
should be able to be calibrated
remotely, or no calibration should be
needed
Preventive maintenance should not
be needed until after 1 y or
1000 samples; an alert should be
included to indicate when
maintenance is needed; should be
able to be calibrated remotely, or no
calibration should be needed
[48, 49]
Data analysis Data analysis should be integrated into the device; a PC should not be required;
exported data should be capable of being analyzed on a separate or networked PC
. . .
Result documentation, data
display
An integrated results screen and the
ability to save and print results should
be included; the device should have a
USB port
An integrated results screen and the
ability to save results should be
included; the device should have a
USB port
. . .
Regulatory requirements Manufacturing of the assay and system should comply with ISO EN 13 485 or higher
standards or regulations andwith ISO IEC 62 304Medical Device Data Systems; the
manufacturing facility should be certified and authorized for use by a regulatory
authority that is a member of the International Medical Device Regulators Forum,
formerly known as the Global Harmonization Task Force; the assay must be
registered for in vitro diagnostic use
. . .
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resistance would require a highly speciﬁc test to avoid high
numbers of false-positive results, unless the patients had previ-
ously been triaged via the detection of rifampin resistance or
unless a false-positive result would have limited adverse impact,
owing to the existence of alternative ﬁrst-line regimens [54].
Isoniazid is a key component of HRZE and the most com-
mon source of monoresistance, and it is thus a good candidate
for inclusion in resistance testing. However, modeling data (at
least for Southeast Asia) show that, on a population level, isoni-
azid testing has minimal incremental value, compared with test-
ing for rifampin alone, to control MDR and isoniazid resistance
[33].This might change if isoniazid monoresistance increases as
more isoniazid preventive therapy is rolled out [34]. Further-
more, the individual beneﬁt of knowing the isoniazid resistance
status to guide therapy is indubitable [54].
Ideally, resistance testing should also inform providers on
decisions about second-line therapy. For second-line drugs,
resistance testing for aminoglycosides and capreomycin, in ad-
dition to ﬂuoroquinolones, would be critical to inform treat-
ment selection for patients with extensively drug-resistant
tuberculosis (XDR) or (pre-) XDR patients (i.e. resistant to
either aminoglycosides or ﬂuoroquinolones). However, if inclu-
sion of these drugs results in an increase in test price or com-
plexity, it may be more cost-effective to test for resistance to
aminoglycosides and capreomycin with a separate, lower vol-
ume test, rather than bundling it with M. tuberculosis detection
and resistance testing to ﬁrst-line drugs.
On the basis of these considerations, the importance of drug
resistance testing in near-patient settings was rated as follows, in
descending order of importance: rifampin, ﬂuoroquinolones
Table 3 continued.
Characteristic Optimal Minimal References
Data export (connectivity and
interoperability)
All data should be able to be exported
(including data on use of the device,
error rates and rates of invalid tests,
and personalized, protected results)
over a USB port and network; network
connectivity should be available
through an Ethernet, Wi-Fi, or GSM/
UMTS mobile broadband modem or a
combination of these; results should be
encoded using a documented standard
(such as HL7) and be formatted as
JSON text; JSON data should be
transmitted through HTTP(S) to a local
or remote server as results are
generated; results should be stored
locally and queued during network
interruptions use of the device, error
rates or rates of invalid tests, and
nonpersonalized results) over a USB
port to be sent as a batch when
connectivity is restored
Integrated ability for all data to be
exported from the device in a user-
friendly format (including data on
use of the device, error rates or
rates of invalid tests, and
nonpersonalized results) over a USB
port
[21, 25, 50]
Electronics and software Should be integrated into the instrument Should be integrated into the
instrument
. . .
Operating temperature/humidity 5°C–50°C at 90% humidity 5°C–40°C at 70% humidity [21, 48]
Reagent kit
Transport No cold chain should be required; should
be able to tolerate stress during
transport for a minimum of 72 h at −15°
C to 50°C
No cold chain required; should be able
to tolerate stress during transport
for a minimum of 72 h at −15°C to
40°C
[21, 25]
Storage and stability 2 y at 5°C–40°C with 90% humidity;
should be able to tolerate stress during
transport for a minimum of 72 h at 50°
C; no cold chain should be required
12 mo at 5°C–35°C with 70%
humidity; should be able to tolerate
stress during transport for a
minimum of 72 h at 50°C; no cold
chain should be required
[21, 25, 48]
Supplies not included in kit None None . . .
Internal quality control Full controls for sample processing, amplification, and detection of M. tuberculosis
should be included
[48, 49]
Training and education 6 work-hours for staff at the level of a
microscopy technician
3 d (or 24 work-hours) for staff at the
level of a laboratory technician
. . .
Adapted with permission from [23].
Abbreviations: GSM, Global System for Mobile Communications; M. tuberculosis, Mycobacterium tuberculosis; PC, personal computer; RIF, rifampin; UMTS,
Universal Mobile Telecommunications System; USB, universal serial bus.
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(including moxiﬂoxacin), isoniazid and pyrazinamide (both of
which were considered of equal importance), and aminoglyco-
sides/capreomycin. Unless inclusion of resistance testing for a
drug adversely affects test cost or performance, all drugs
would be included under optimal conditions.
The sensitivity of a rapid molecular method to detect drug
resistance can be judged in comparison to a genotypic (se-
quencing) or phenotypic (culture-based) method. Optimally,
new tests should detect individual single-nucleotide polymor-
phisms (SNPs) encoding rifampin, ﬂuoroquinolone, pyrazina-
mide, isoniazid, and aminoglycoside/capreomycin resistance
at least 98% of the time, comparison with sequencing. This
threshold should be considered minimally acceptable for rifam-
pin only; for the other drugs, the sensitivity for detection of in-
dividual SNPs should be ≥95%. With a phenotypic comparator,
resistance to any given drug should be detected with ≥95%
sensitivity. Minimally, the same speciﬁcation is maintained
for rifampin resistance but decreases to 90% for detection of ﬂu-
oroquinolones, pyrazinamide, isoniazid, and aminoglycosides/
capreomycin [1, 28, 37–42].Optimal and minimal speciﬁcity re-
quirements are identical: ≥98% for any drug resistance testing,
compared with either phenotypic resistance testing or the se-
quencing reference standard [1, 28, 37–39, 42].
Operational Characteristics
Because of conditions that prevail in microscopy centers in
high-burden countries, tests used in these centers should be ro-
bust with very simple sample preparation and minimal opera-
tional requirements (Table 3). The degree to which a test gets
adopted will likely depend as much on how well a new product
meets the speciﬁed operational characteristics as on cost or per-
formance [8, 20].
Power Requirements/Tolerance to Environmental
Conditions
Ideally, a test should be battery operated (with a functional life
of 24 hours when fully charged) and include a recharging sol-
ution (eg, solar) and circuit protector. At a minimum, the plat-
form should be capable of being powered by a standard
electrical supply and have a backup with an uninterrupted
power supply (UPS) to complete any ongoing testing in case
of failure of the AC power supply. The UPS and a circuit pro-
tector must be integrated within the system. Tolerance to high
temperatures (optimally, up to 50°C) and high humidity (90%)
is a key criterion for durability and performance of testing in
many tuberculosis-endemic settings (Table 3).
Maintenance, Calibration, and Integrated Controls
Required maintenance should be infrequent (optimally, only
every 2 years) with a maintenance alert indicating the need for
evaluation. Furthermore, it will be essential that only simple
tools and minimal expertise are necessary to do the maintenance,
given that service visits are unlikely to be feasible outside of urban
settings [48, 49]. No calibration should be required, or remote
calibration should be feasible. Full process control, (ie, speciﬁcally
controlling for sample processing, ampliﬁcation, and detection)
should be integrated into testing [48, 49].
Time to Result
The need for a rapid turnaround time, the possibility of batch-
ing and random access, and the testing of multiple samples at
the same time are interrelated in their importance, as all of
these will deﬁne how many samples can be tested per day and
how quickly the patient will receive results [45, 46]. Optimally,
the turnaround time should be <30 minutes (for detection and
resistance testing); although a minimum of 2 hours for resis-
tance testing alone would be acceptable, ideally, detection of
M. tuberculosis would be reported more rapidly, to prevent
loss to follow-up [45, 46].
Sample Preparation
The requirements for the manual sample preparation (ie, the
total number of hands-on steps after obtaining the sample)
and the results documentation are important characteristics of
a test, considering the expertise of the user at the microscopy
center level [21, 25]. Optimally, no manual steps or only
1 step should be necessary (and any steps that require precision
volume control or precision time steps should be excluded).
Connectivity/Data Export
Although Internet access is not widely available in the settings
of intended use, mobile phone capacity is frequently available,
even at microscopy centers [21, 25]. This could be leveraged for
patient management, quality control, device and supply chain
management, and surveillance [50]. Platforms should, ideally,
therefore enable full export of data (on device use, error/invalid
rates, and personalized, protected results) over a universal serial
bus (USB) port and network. The network connectivity should
be through Ethernet, Wi-Fi, and/or Global System for Mobile
Communications/Universal Mobile Telecommunications Sys-
tem mobile broadband modem. Results should be encoded
using a documented standard (such as HL7). At minimum,
the platform should have the integrated ability to fully export
data (on device sue, error/invalid rates, and nonpersonalized
results) from the device in a user-friendly format over a USB
port [21, 25].
Cost
Limited data are available on acceptable cost from the perspec-
tives of developers, national treatment programs, and global
funders [55]. A higher price than that of the available technol-
ogies (Xpert MTB/RIF and Hain Genotype MTBDRplus are
currently available under preferential pricing for approximately
$10/test) would be justiﬁed only if the new tests bring substan-
tial added value in terms of improved performance, greater
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suitability for decentralization, and the number of drugs for
which resistance can be detected. Cost-effectiveness modeling
work is ongoing. A summary of an affordability analysis per-
formed by Pantoja et al is presented as part of this Supplement.
Further discussions on an acceptable cost range are necessary as
new technologies become available to understand the cost of
goods, development, and manufacturing. As the added value
in respect to performance and operational characteristics in-
creases, so too might the acceptable costs (to donors like The
Global Fund and countries).
DISCUSSION
Expanded availability of drug-susceptibility testing is needed
to improve individual patient level outcomes and, as part of
tuberculosis control efforts, to improve management of drug re-
sistance. Because of the slowness and complexity of convention-
al methods, resistance testing is almost never performed at
peripheral centers, and results of such tests would therefore
not inform selection of ﬁrst-line therapy when multiple
regimens are available [1]. However, testing in the microscopy
center requires that a test meet certain operational characteris-
tics to maintain the performance demonstrated in controlled
settings [56, 57]. Resistance testing at peripheral settings
needs to be complemented by centralized surveillance and test-
ing to inform individualized therapy.
While great strides have been made to improve the under-
standing of the needs for detection and resistance testing and
the various requirements for test use in different healthcare set-
tings, certain key data gaps remain. To improve our understand-
ing of the distribution of drug resistance, the correlation of
resistance between drugs, and the trajectories of resistance de-
velopment over time, population-level surveillance data for dif-
ferent drugs in different regions is necessary. Rifampin and
isoniazid data and trajectories are available over recent years,
but the understanding of the prevalence of resistance for
other drugs is conﬁned to isolated publications [1, 32, 35]. A
surveillance effort by the WHO in 5 countries will shed light
on the prevalence of pyrazinamide and ﬂuoroquinolone resis-
tance and the correlation with rifampin resistance. This work
is complemented by parallel surveillance work in India and
China.
Data are also needed on the correlation of mutations with
phenotypic results and clinical outcomes and the association
with cross-resistance. Here, the scientiﬁc community has to
work to increase understanding and inform test developers.
Efforts to pool sequencing data from different studies and sur-
veillance projects will be essential to better understand the mo-
lecular basis of resistance [58]. A coordinated effort to compile
the available data across different geographic regions into a da-
tabase that contains the appropriate meta-data, is vetted and
quality controlled, and is readily accessible to all stakeholders
is being initiated by FIND, the New Diagnostics Working
Group, and the CPTR [59]. Monitoring of resistance for new
drugs (eg, bedaquiline and delamanid) and integration into mo-
lecular drug-susceptibility testing should also be considered as
they become more widely used.
Further implementation research is necessary to better un-
derstand barriers to diagnosis and treatment, as well as over-
treatment. What is necessary to ensure that test results lead to
earlier treatment and minimize loss to follow-up? Data from the
phase 3 drug trials and postintroduction surveillance will fur-
ther guide the understanding of trade-offs of incorrectly identi-
fying sensitivity or resistance (eg, what percentage of patients
would acquire resistance to moxiﬂoxacin and Pa-824 if a test
failed to identify pyrazinamide resistance and the patient was
only treated with 2 effective drugs?).
This ongoing work will aid the reﬁnement of the speciﬁca-
tions outlined in the TPP, making it a dynamic tool for commu-
nication with investors, partners, and stakeholders and a tool
for tracking results toward appropriate assays for testing drug
susceptibility in tuberculosis.
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